Genentech - A Member of the Roche Group

/ Scientists

Focus on Neuroscience

The treatment of most neurological and psychiatric disorders remains a huge unmet need. Our Neuroscience Research and Drug Discovery program is aimed at discovering and developing breakthrough medicines for patients with major diseases of the nervous system, such as Alzheimer's diseases. Right now we're focused on several neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Glaucoma, and Amyotrophic Lateral Sclerosis (Lou Gehrig's disease).

By using a multidisciplinary approach and a wide range of technologies, we hope to tackle the fundamental mechanisms underlying the biology and the diseases of the nervous system, and to translate these discoveries into innovative therapies for neurological disorders.

Recent Publications

Science Translational Medicine, May 2013
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
Read Article

Proceedings of the National Academy of Sciences, March 2013
DLK initiates a transcriptional program that couples apoptotic and regenerative responses to axonal injury
Read Article

Science Translational Medicine, December 2012
Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations
Read Article

Nature, July 2012
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline.
Read Article

Journal of Neuroscience, July 2012
An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ
Read Article

Science Translational Medicine, May 2011
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Read Article